7,500 Shares in Vera Therapeutics, Inc. (NASDAQ:VERA) Purchased by AlphaCentric Advisors LLC

AlphaCentric Advisors LLC purchased a new position in Vera Therapeutics, Inc. (NASDAQ:VERA) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 7,500 shares of the company’s stock, valued at approximately $332,000.

Several other institutional investors also recently modified their holdings of VERA. Capstone Investment Advisors LLC bought a new position in shares of Vera Therapeutics in the 1st quarter worth about $248,000. FORA Capital LLC bought a new position in shares of Vera Therapeutics in the 1st quarter worth about $692,000. Jennison Associates LLC bought a new position in shares of Vera Therapeutics in the 1st quarter worth about $3,231,000. SG Americas Securities LLC increased its stake in shares of Vera Therapeutics by 54.9% in the 1st quarter. SG Americas Securities LLC now owns 11,941 shares of the company’s stock worth $515,000 after acquiring an additional 4,232 shares in the last quarter. Finally, Swiss National Bank increased its stake in shares of Vera Therapeutics by 27.7% in the 1st quarter. Swiss National Bank now owns 62,200 shares of the company’s stock worth $2,682,000 after acquiring an additional 13,500 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors.

Vera Therapeutics Price Performance

Shares of VERA stock opened at $45.17 on Tuesday. The company has a 50 day moving average price of $40.65 and a 200-day moving average price of $38.90. Vera Therapeutics, Inc. has a 52 week low of $9.88 and a 52 week high of $50.78. The company has a current ratio of 21.43, a quick ratio of 21.43 and a debt-to-equity ratio of 0.15.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). On average, sell-side analysts predict that Vera Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Beth C. Seidenberg sold 1,177 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $42.01, for a total value of $49,445.77. Following the transaction, the director now owns 160,376 shares of the company’s stock, valued at approximately $6,737,395.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CEO Marshall Fordyce sold 15,625 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $37.50, for a total value of $585,937.50. Following the transaction, the chief executive officer now owns 307,972 shares of the company’s stock, valued at approximately $11,548,950. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Beth C. Seidenberg sold 1,177 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $42.01, for a total transaction of $49,445.77. Following the completion of the transaction, the director now directly owns 160,376 shares in the company, valued at approximately $6,737,395.76. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 104,398 shares of company stock valued at $4,376,163. 21.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

VERA has been the subject of a number of analyst reports. Guggenheim raised their price objective on shares of Vera Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research note on Monday, October 28th. Scotiabank initiated coverage on shares of Vera Therapeutics in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $60.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and set a $107.00 price objective on shares of Vera Therapeutics in a research note on Tuesday, October 1st. Evercore ISI upgraded shares of Vera Therapeutics to a “strong-buy” rating in a research note on Monday, September 16th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Vera Therapeutics from $62.00 to $72.00 and gave the company an “overweight” rating in a research note on Tuesday, September 3rd. One analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $53.56.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.